Investing.com -- AstraZeneca reported higher revenue and core earnings in the first quarter, as strong demand for its oncology and rare-disease treatments drove double-digit sales growth across key product lines.

The U.K. drugmaker generated $15.29 billion in revenue for the period, up from $13.59 billion a year earlier and ahead of the analyst consensus of $14.94 billion, according to estimates compiled by Visible Alpha. Excluding currency movements, revenue rose 8% year-over-year.

Revenue from oncology products grew 16% year-on-year at constant currency to $6.8 billion. The segment accounts for 44% of Astrazeneca’s group revenue.

"We delivered strong growth in Q1 2026, with Total Revenue above $15 billion, demonstrating our consistent commercial execution," said CEO Pascal Soriot.

"We continue to invest in our commercial capabilities as we prepare for multiple launches, look forward to further readouts anticipated this year, and remain on track to achieve our ambition for 2030 and beyond," he added.

Among individual treatments, Imfinzi — used to treat bladder and lung cancers — posted a 30% revenue jump to $1.7 billion. Tagrisso, a lung cancer therapy, rose 5% to $1.8 billion, while Enhertu, which targets several forms of breast and gastric cancer, surged 34% to $831 million.

Core earnings per share, the company’s preferred profit metric which strips out exceptional items, came in at $2.58, up 5% at constant currency and above the analyst estimate of $2.54. Core operating profit rose 12% to $4.25 billion.

Net profit for the quarter increased to $3.08 billion from $2.92 billion a year earlier.

AstraZeneca reiterated its full-year guidance, forecasting revenue growth in the mid-to-high single-digit percentage range and core EPS growth in the low double digits.